Syndax Pharmaceuticals

SNDX

Market cap $1.36B

Overview Fund Activity

15.84 USD

+0.29

1.86%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

15.84

0.00

0%

1 day

1.86%

5 days

-1.92%

1 month

0.64%

3 months

58.56%

6 months

21.47%

Year to date

12.5%

1 year

-12.97%

5 years

-9.38%

10 years

31.89%

About: Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Employees: 184

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

28% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 67

15% more call options, than puts

Call options by funds: $14.4M | Put options by funds: $12.5M

3% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 30

0.86% more ownership

Funds ownership: 117.38% [Q1] → 118.24% (+0.86%) [Q2]

0% less funds holding

Funds holding: 218 [Q1] → 217 (-1) [Q2]

24% less capital invested

Capital invested by funds: $1.26B [Q1] → $953M (-$302M) [Q2]

30% less funds holding in top 10

Funds holding in top 10: 10 [Q1] → 7 (-3) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$24

52% upside

Avg. target

$42

165% upside

High target

$56

254% upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Stifel Bradley Canino	$44	Buy Reinstated	10 Sep 2025
Goldman Sachs Corinne Johnson	$24	Buy Maintained	5 Sep 2025
Citigroup Yigal Nochomovitz	$51	Buy Maintained	5 Aug 2025
BTIG Justin Zelin	$56	Buy Maintained	5 Aug 2025
UBS David Dai	$35	Buy Maintained	15 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about SNDX published over the past 30 days

Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC

FDA approval of revumenib for r/r KMT2Ar AML patients drives strong revenue growth for Syndax Pharmaceuticals, with Q2 2025 sales up 43% quarter-over-quarter. Upcoming FDA Priority Review decision for sNDA in r/r mNPM1 AML offers a significant near-term catalyst, with a PDUFA date set for October 25, 2025. Expansion into metastatic MSS colorectal cancer represents a major pipeline opportunity, targeting a large market with data expected by the end of 2025.

Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025 the Company granted inducement awards to purchase up to 167,400 shares of common stock to 11 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference Transcript

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Citi's Biopharma Back to School Conference September 2, 2025 4:45 PM EDT Company Participants Keith Goldan - CFO, Treasurer & Chief Accounting Officer Steven Closter - Chief Commercial Officer Nicholas Botwood - Head of Research & Development and Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst Welcome, everyone, to the, I believe, the last session of the first day of Citi's Biopharma Back-to-School Summit. I'm Yigal Nochomovitz, biotech analyst here at Citi.

Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference Transcript

Zacks Investment Research

Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade

The mean of analysts' price targets for Syndax (SNDX) points to an 112.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade

Syndax Announces Participation in September Investor Conferences

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

Syndax Announces Participation in September Investor Conferences

Zacks Investment Research

Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?

The mean of analysts' price targets for Syndax (SNDX) points to a 158.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?

Syndax Pharmaceuticals: A Tale Of Two Drug Launches

Shares of Syndax Pharmaceuticals are still down 45% over the past three years. The Q2 report was encouraging on multiple fronts with a strong start for the Revuforj launch in KMT2A AML and Niktimvo launch in chronic GVHD. Incyte is the ideal partner for GVHD, being highly familiar with this space and the 50/50 split in the US provides a significant downside cushion to investors.

Syndax Pharmaceuticals: A Tale Of Two Drug Launches

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2025 the Company granted inducement awards to purchase up to 48,600 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals: The Story Brightens

Syndax Pharmaceuticals just delivered strong second quarter results, beating expectations, and management also increased its long-term market opportunity projections. Both Revuforj and Niktimvo are driving rapid revenue growth, with management now targeting $10 billion in peak sales for both drugs combined. Analysts remain bullish and profitability could arrive by FY 2028, a year earlier than consensus estimates before Q2 numbers came out.

Syndax Pharmaceuticals: The Story Brightens

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Keith Alan Goldan - CFO, Treasurer & Chief Accounting Officer Michael A. Metzger - CEO & Director Nicholas Botwood - Head of Research and Development and Chief Medical Officer Sharon Klahre Peter Richard Lawson - Vice President of Investor Relations & Communications Steven Closter - Chief Commercial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Dingding Shi - Jefferies LLC, Research Division Jason Eron Zemansky - BofA Securities, Research Division Justin Reid Zelin - BTIG, LLC, Research Division Kevin Strang - Goldman Sachs, Research Division Mayank Mamtani - B.

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™